Redeye revisits its market share assumptions for BONESUPPORT’s extremities business.
Adj. EBITA SEK 180m (-16% vs. ABGSCe 214m) Consensus full-year EBITA should come down by mid-to-high...
Redeye strengthens its positive view of Vertiseit following a solid Q1 report, new long-term goals, ...
Redeye updates its outlook on Hansa Biopharma, anticipating improved launch support during 2024 and ...
Redeye comments on Freemelt’s first industrial printer (eMelt) order in the US and provides a previe...
Redeye is encouraged to see progress in Impact Coatings’ Chinese coating center.
We cut '24e-'26e adj. EBITA by 8-4% Should break seven-quarter negative org.
'24e-'26e ARR cut by 2-3% on continued macro weakness B2C business momentum likely to return in H2'2...
Tangiamo Touch Technology meddelade den 16 april 2024 att bolaget har erhållit en order värd cirka 1...
Försäljningen i Q4 minskade något jämfört med samma period i fjol.
Fastighetsmarknaden har en alltmer balanserad antydan och fastighetsbolaget fortsätter att stärka up...
Q1: 33% y-o-y ARR growth and 15% adj. EBITDA margin All FY'24 guidance items upgraded once again Con...
Wood M&A lifts '24e-'26e EPS by 4-6%, EBITA up 12-17% Share now trading at 9.
SRV publishes its Q1/24 figures on Thursday 25th of April.
VIMAB Group är en industrikoncern verksamma inom miljö, elektrifiering och near-shoring.
Redeye leaves an initial comment following the Q1 report published by Magle this morning.
Continued weakenss in Genetics holding back sales growth Good growth in Consumables and Technology E...
Redeye provides its initial take on ADDvise’s Q1 2024 report, which came in broadly below our estima...
Ahead of CapMan's Q1 report on 3 May, our SOTP-based fair value range of EUR 2.
We lower '24e-'26e adj. EBITA by 10-3%... ...on continued weakness in macro data '24e EV/EBITA of ~8...
